Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Rousselot B V currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is located within 1 distinct art unit, reflecting a focused technical scope for the company's current patent activity. The concentration in 1 art unit allows the company to tailor its prosecution approach to the specific guidelines of that USPTO division.
The prosecution is being handled by 1 distinct examiner, GARYU, LIANKO G, who is also the busiest examiner with 1 pending office action. With 1 distinct examiner for the 1 pending action, the company's immediate patent success is tied to a single point of contact. This one-to-one ratio simplifies the management of the portfolio but makes the outcome highly dependent on the specific examiner's review.
The focus on Biotechnology & Pharmaceuticals ensures that the legal strategy remains aligned with the specific patentability standards of that technology sector. With only 1 pending action, the company can dedicate its resources to resolving the specific issues raised by GARYU, LIANKO G to advance the application toward allowance.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GARYU, LIANKO G | 1 | 66.0% | +45.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19104383 | THE USE OF FATTY ALCOHOL POLYGLYCOL ETHER TO REDUCE ENDOTOXIN ACTIVITY AND/OR ENDOTOXINS IN COLLAGEN-CONTAINING AND/OR COLLAGEN-DERIVED PRODUCTS | GARYU, LIANKO G | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19104383 | THE USE OF FATTY ALCOHOL POLYGLYCOL ETHER TO REDUCE ENDOTOXIN ACTIVITY AND/OR ENDOTOXINS IN COLLAGEN-CONTAINING AND/OR COLLAGEN-DERIVED PRODUCTS | GARYU, LIANKO G | 27d |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19104383 | THE USE OF FATTY ALCOHOL POLYGLYCOL ETHER TO REDUCE ENDOTOXIN ACTIVITY AND/OR ENDOTOXINS IN COLLAGEN-CONTAINING AND/OR COLLAGEN-DERIVED PRODUCTS | GARYU, LIANKO G | 1654 | §101§103§112 | Final Rejection | 27d | Pending | Feb 18, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial